The recent spreading of new SARS-CoV-2 variants, carrying several mutations in the spike protein, could impact immune protection elicited by natural infection or conferred by vaccination. In this study, we evaluated the neutralizing activity against the viral variants that emerged in the United Kingdom (B.1.1.7), Brazil (P.1), and South Africa (B.1.351) in human serum samples from hospitalized patients infected by SARS-CoV-2 during the first pandemic wave in Italy in 2020. Of the patients studied, 59.5% showed a decrease (≥2 fold) in neutralizing antibody titer against B.1.1.7, 83.3% against P.1, and 90.5% against B.1.351 with respect to the original strain. The reduction in antibody titers against all analyzed variants, and in particular P.1 and B.1.351, suggests that previous symptomatic infection might be not fully protective against exposure to SARS-CoV-2 variants carrying a set of relevant spike mutations.
【저자키워드】 SARS-CoV-2, variants of concern, Neutralizing activity, 【초록키워드】 Brazil, vaccination, pandemic, Mutation, B.1.351, SARS-CoV-2 variant, Italy, hospitalized patients, variants, Spike protein, Neutralizing activity, South Africa, Viral, SARS-CoV-2 variants, B.1.1.7, P.1, Antibody titer, Viral variants, spike mutations, natural infection, United Kingdom, viral variant, human serum, Antibody titers, Neutralizing antibody titer, Protective, immune protection, symptomatic infection, exposure to, decrease, new SARS-CoV-2, analyzed, the patient, evaluated, hospitalized patient, the spike protein, reduction in, elicited, 【제목키워드】 COVID-19, activity, P.1, concern,